Depression

Magic Mushrooms in laboratory. Psilocybin science and research.
#Depression #Plant-based #Psilocybin #Psychedelics #Treatment-resistant depression

Where is the promise for plant-based medicines? Part 2: Psilocybin 

In the second part of this series of articles focused on plant-based medicines, DDW’s Megan Thomas evaluates the use of psilocybin in drug discovery. The first part explored medical cannabis.  What is the regulatory landscape of psilocybin?  Psilocybin is a naturally occurring psychedelic compound that is produced by more than… Read More

#Business & Investment #Exclusive Content #Regulatory

Human brain
#AlzeCure Pharma #Antidepressants #Depression #Preclinical investigations #Psychiatry

Preclinical study proves antidepressant effects of drug

The results of a preclinical study supporting the antidepressive effects of AlzeCure Pharma’s NeuroRestore ACD856 have been published in the journal Psychopharmacology. The article focuses on new data showing that ACD856, the lead and clinical drug candidate in the NeuroRestore platform, exhibits antidepressant effects in various… Read More

#Editor's Choice #News

Mental health
#Antidepressants #Anxiety disorder #Depression #Drug discovery #Mental health #Neuroscience #Psychiatry

World Wellbeing Week 2023: Celebrating drug discovery innovation

DDW’s Diana Spencer provides an overview of the latest innovations in drug discovery for mental health. World Wellbeing Week was created to celebrate the many aspects of wellbeing, from meaningful, purposeful work to financial security, physical, mental and emotional health, social resilience and empathic corporate and civic leadership, community relations… Read More

#Exclusive Content

Hormones in the brain concept
#Antidepressants #Depression #Evecxia Therapeutics #Major depressive disorder #Phase I trial #Psychiatry

New adjunctive antidepressant elevates serotonin in Phase I trial

Evecxia Therapeutics has reported favourable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a Phase I trial of EVX-101 in healthy volunteers treated with escitalopram. The company is also planning a Phase II adjunctive EVX-101 trial in patients with major depressive disorder (MDD) responding inadequately to a… Read More

#News

Nasal spray
#Beckley Psytech #Depression #Phase II trial #Psychiatry #Treatment-resistant depression

Phase IIa study begins in treatment resistant depression

Beckley Psytech has initiated a Phase IIa study investigating BPL-003, a proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), for treatment resistant depression (TRD).  Depression affects around 280 million people around the world, but 30% of those living with the condition are resistant to available antidepressant medications,… Read More

#News

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

Podcast: Keep up-to-date on the latest industry news

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  The industry has seen breakthroughs announced in malaria treatment, epilepsy and major… Read More

#News

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

This week in drug discovery (28 November – 2 December)

News round-up for 28 November – 2 December by DDW Digital Content Editor Diana Spencer  The last seven days have seen breakthroughs announced in malaria treatment, epilepsy and major depressive disorders. The NHS in England has fast tracked another cancer drug, and, in Covid-19 news, researchers have… Read More

#News

Magic mushrooms
#Depression #Mental health #Psilocybin #Psychedelics #The New England Journal of Medicine #Treatment-resistant depression #Trial data

Study shows ‘magic mushrooms’ could treat depression 

Psilocybin, a psychedelic derived from mushrooms, has been proven effective as a therapy for treatment-resistant depression (TRD) in the largest study of its kind.  The results of COMPASS Pathways’ Phase IIb trial have been published in The New England Journal of Medicine (NEJM). Read More

#News #Trending News

#CNS #Depression #Start-ups

Start-up looks to treat depression  

A new start-up has launched with an aim of developing therapeutics that address synaptic dysfunction in patients suffering from central nervous system (CNS) disorders.   Gate Neurosciences was founded in 2019 by a team of neuroscientists with the goal of addressing the urgent need for more effective treatments for CNS disorders,… Read More

#Business & Investment #News

#Clinical trials #Depression #Drug development #GlobalData

Novel antidepressant has blockbuster potential

Following the news that the Food and Drug Administration (FDA) has accepted Axsome Therapeutics’ new drug application (NDA) for its novel antidepressant therapy AXS-05 and granted it priority review, GlobalData commented that it would be “a blockbuster drug” by 2026, estimating global sales of approximately US$1.3 billion by 2029. Philippa… Read More

#News #Trending News

#Clinical trial #Depression #Drug development #Drug discovery #Research

Magic mushroom compound performs as well as leading antidepressant

In a small study carried out by researchers at the Centre for Psychedelic Research at Imperial College London, it was found that psilocybin, the active compound in magic mushrooms, may be at least as effective as a leading antidepressant medication in a therapeutic setting. In a rigorous trial which assessed… Read More

#News